BioDlink International Company Limited (referred to hereafter as “BioDlink”) filed its Monthly Return for the period ended 31 March 2026, confirming that the company’s share structure and public float remained stable throughout the month. The statutory filing was submitted to Hong Kong Exchanges and Clearing Limited on 09 April 2026.

Total Issued Shares • Ordinary shares in issue (excluding treasury shares) closed the month unchanged at 772.79 million. • No treasury shares were held, repurchased, cancelled or issued. • Consequently, the total number of issued shares stayed at 772.79 million, identical to the figure at the end of February 2026.

Public Float Status • BioDlink confirmed compliance with the Main Board’s minimum 25% public-float threshold as at 31 March 2026.

Share Option Activity • The Pre-IPO Share Option Scheme, adopted on 20 February 2013 with an exercise price of US$0.286 (HK$2.2335) per share, showed 7.63 million outstanding options at both the beginning and end of March. • No new options were granted, exercised, cancelled or lapsed; therefore, no new shares were issued and no funds were raised under the scheme during the month.

Other Securities • The company reported no outstanding warrants, convertible securities, Hong Kong depositary receipts or other equity-linked instruments.

Board Confirmation The filing was signed by Joint Company Secretary Lui Wing Yat Christopher, who affirmed that all regulatory requirements related to the company’s securities activities in March 2026 were duly observed.